TY - JOUR
T1 - Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation
AU - Pasvolsky, Oren
AU - Shargian, Liat
AU - Rozovski, Uri
AU - Wolach, Ofir
AU - Ram, Ron
AU - Shapira, Michael Y.
AU - Avni, Batia
AU - Stepensky, Polina
AU - Israeli, Moshe
AU - Vidal-Fisher, Liat
AU - Shpilberg, Ofer
AU - Raanani, Pia
AU - Yeshurun, Moshe
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.
AB - Platelet recovery after allogeneic umbilical cord blood (UCB) transplantation is delayed compared to other graft sources. We conducted a multicenter phase 2a study to explore whether eltrombopag, a thrombopoietin-receptor agonist, would enhance platelet recovery after UCB transplantation. Between 02/2013 and 07/2016, 12 (10 adults, 2 children) individuals (median age 50; range 6–74 years) with hematological malignancies in complete remission were enrolled. Eltrombopag was given for a median of 76 (range 15–175) days and was safe even at doses of 300 mg/day. Median time to neutrophil engraftment was 23 (range 16–40) days. Median time to platelets >20,000/µl and >50,000/µl was 55 (range 25–199) and 66 (range 31–230) days, respectively. A historical cohort comparison did not reveal an advantage for eltrombopag. In conclusion, in the present study eltrombopag seems safe. Based on our limited data, it seems unlikely that eltrombopag could enhance platelet engraftment after UCB transplantation.
KW - Eltrombopag
KW - allogeneic hematopoietic cell transplantation
KW - platelet engraftment
KW - umbilical cord blood
UR - http://www.scopus.com/inward/record.url?scp=85106310796&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1929957
DO - 10.1080/10428194.2021.1929957
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34013829
AN - SCOPUS:85106310796
SN - 1042-8194
VL - 62
SP - 2747
EP - 2754
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -